BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AFSSI Sciences de la Vie - ECPv5.14.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AFSSI Sciences de la Vie
X-ORIGINAL-URL:https://www.afssi.fr
X-WR-CALDESC:Events for AFSSI Sciences de la Vie
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190128
DTEND;VALUE=DATE:20190131
DTSTAMP:20260526T031310
CREATED:20190104T101053Z
LAST-MODIFIED:20190104T101053Z
UID:17039-1548633600-1548892799@www.afssi.fr
SUMMARY:3rd Microbiome Movement - Drug Development 2019
DESCRIPTION:Despite the scientific communities progress in translating microbiome R&D into promising therapeutic candidates\, academic and pharmaceutical leaders continue to identify the causal role of the human microbiome in disease to create treatments with consistent clinical outcomes and predictable molecular mechanisms. \nPart of the established Microbiome Movement\, the 3rd Microbiome Movement – Drug Development Europe returns as the industry-defining forum to help discover\, develop and deliver the next generation of microbiome-based therapeutic and diagnostic candidates to market. \nAbout the event\nRecent breakthroughs in DNA sequencing\, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota\, an interconnected community of symbiotic\, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human microbiome on human health and disease\, recent efforts have sought to harness this research to create microbiome-based therapeutics. \nSituated at the heart of therapeutic R&D\, the Microbiome Movement – Drug Development Summit kick starts 2019\, once again to help large pharma\, biotech and academic institutions accelerate the discovery\, clinical development of safe\, effective and commercially scalable microbiome therapeutics across a broad range of disease indications. \nSet to tackle the greatest scientific\, regulatory\, clinical\, manufacturing and commercialisation challenges across the entire drug development value chain\, this meeting will showcase leading industry case studies focused on enhancing the application of novel technologies to standardise results\, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products. \nGet the program\n  \n\n \nRegister now
URL:https://www.afssi.fr/event/3rd-microbiome-movement-drug-development-2019/
LOCATION:Novotel Paris Est\, 1 Avenue de la République\,\, Bagnolet\,\, 93177\, France
CATEGORIES:Evénement filière
ATTACH;FMTTYPE=image/jpeg:https://www.afssi.fr/wp-content/uploads/2019/01/3rd-Microbiome-Movement-Drug-Development-Summit-Europe-2019.jpg
END:VEVENT
END:VCALENDAR